Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1981 1
1986 1
1987 1
1989 1
1997 1
1998 1
2001 1
2002 3
2003 5
2004 9
2005 1
2006 4
2007 4
2008 1
2009 6
2010 4
2011 6
2012 17
2013 9
2014 23
2015 17
2016 25
2017 17
2018 22
2019 18
2020 2
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 23011861

180 results
Results by year
Filters applied: . Clear all
Page 1
[Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids].
Oreja-Guevara C. Oreja-Guevara C. Rev Neurol. 2012 Oct 1;55(7):421-30. Rev Neurol. 2012. PMID: 23011861 Free article. Review. Spanish.
Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
Russo EB. Russo EB. Neurology. 2003 Feb 25;60(4):729-30; author reply 729-30. doi: 10.1212/wnl.60.4.729-a. Neurology. 2003. PMID: 12601130 No abstract available.
Sativex for the management of multiple sclerosis symptoms.
Perras C. Perras C. Issues Emerg Health Technol. 2005 Sep;(72):1-4. Issues Emerg Health Technol. 2005. PMID: 16317825
Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
Syed YY, McKeage K, Scott LJ. Syed YY, et al. Drugs. 2014 Apr;74(5):563-78. doi: 10.1007/s40265-014-0197-5. Drugs. 2014. PMID: 24671907 Review.
Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.
Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U, Schnelle M, Reif M. Vaney C, et al. Mult Scler. 2004 Aug;10(4):417-24. doi: 10.1191/1352458504ms1048oa. Mult Scler. 2004. PMID: 15327040 Clinical Trial.
Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.
Collin C, Davies P, Mutiboko IK, Ratcliffe S; Sativex Spasticity in MS Study Group. Collin C, et al. Eur J Neurol. 2007 Mar;14(3):290-6. doi: 10.1111/j.1468-1331.2006.01639.x. Eur J Neurol. 2007. PMID: 17355549 Clinical Trial.
Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation.
Giacoppo S, Bramanti P, Mazzon E. Giacoppo S, et al. Mult Scler Relat Disord. 2017 Oct;17:22-31. doi: 10.1016/j.msard.2017.06.015. Epub 2017 Jun 27. Mult Scler Relat Disord. 2017. PMID: 29055461 Review.
Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Riva N, Mora G, Sorarù G, Lunetta C, Ferraro OE, Falzone Y, Leocani L, Fazio R, Comola M, Comi G; CANALS Study Group. Riva N, et al. Lancet Neurol. 2019 Feb;18(2):155-164. doi: 10.1016/S1474-4422(18)30406-X. Epub 2018 Dec 13. Lancet Neurol. 2019. PMID: 30554828 Clinical Trial.
Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence.
Ziemssen T. Ziemssen T. Neurodegener Dis Manag. 2019 Apr;9(2s):1-2. doi: 10.2217/nmt-2018-0048. Epub 2019 Jan 18. Neurodegener Dis Manag. 2019. PMID: 30657019
[There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
Bazinski H, Jensen HB, Stenager E. Bazinski H, et al. Ugeskr Laeger. 2015 May 11;177(20):956-60. Ugeskr Laeger. 2015. PMID: 26535431 Review. Danish.
180 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page